Introduction
product 8 as a pale yellow oil (36 g, 97.4%), which was used directly in the next step. The 1 H NMR spectrum corresponded to that reported by Stevens & De Kimpe (1996) .
3,3-Dimethoxy-1-cyclobutylmethanol (9) . A solution of ester 8 (35 g, 0.2 mol) in THF (100 ml) was added dropwise with stirring to a suspension of LiAlH 4 (5.74 g, 0.15 mol) in THF (150 ml) at 0°C. The stirring was continued at room temperature for 4 h, the mixture was cooled to 0°C, water (5.8 ml) was added dropwise followed by 15% NaOH (5.8 ml). The solids were filtered off and they were washed with EtOAc (200 ml), filtrate was evaporated and residue was chromatographed on a silica gel column using hexanes:EtOAc (3:2→1:1) as an eluant to give product 9 as a colourless oil (25 g, 85%). 1 H NMR (CDCl 3 ) δ 1.84-1.88 (m, 1H, H 1 ), 2.20-2.28 (m, 4H, H 2 +H 4 ), 3.11 (s, 3H) and 3.13 (s, 3H, Me), 3.61 (t, 2H, J=6.0 Hz, 1-CH 2 ). The 13 C NMR spectrum corresponded to that reported by Stevens & De Kimpe (1996) . .
1-
Sodium hydride (60% oil dispersion, 400 mg, 10 mmol) was added to a solution of compound 9 (1.23 g, 8.31 mmol) in DMF (20 ml) with stirring at 0°C. The stirring was continued for 3 h, benzyl bromide (1.2 ml, 10 mmol) was added, reaction mixture was stirred at room temperature for 16 h whereupon it was quenched by pouring into a saturated solution of NaCl (50 ml). The mixture was extracted with ether (3×200 ml), organic phase was washed with water, it was dried (Na 2 SO 4 ) and evaporated. The residue was chromatographed on a silica gel column in hexanes:EtOAc (25:1→19:1) to furnish product 10 (1.77 g, 75%) as a colourless oil. 1 H NMR (CDCl 3 ) δ 1.83-1.90 and 2.26-2.37 (m, 5H, H 1 , H 2 +H 4 ), 3.12 (s, 3H) and 3.15 (s, 3H, Me, acetal), 3.48 (d, 2H, J=6.9 Hz, 1-CH 2 ), 4.52 (s, 2H, CH 2 of Bn), 7.34 (m, 5H, Ph); 13 C NMR 24.9 (C 1 ), 35.0 (C 2 +C 4 ), 48.4, 48.7 (Me, acetal) , 73.2, 74.7 (1-CH 2 , CH 2 of Bn), 101.1 (C 3 ), 127.8, 127.9, 128.6, 138.7 (Ph) ; EI-MS 205 (M-CH 3 O, 100.0), 145 (M-Bn, 1.0). Compound 11 was used in the next step without chromatographic purification. . A solution of compound 10 (17.5 g, 74.2 mmol) in acetone:water (2:1, 300 ml) and p-toluenesulfonic acid hydrate (1 g, 5.25 mmol) was stirred for 16 h at room temperature. Acetone was evaporated, the aqueous phase was extracted with ether (3×100 ml), organic phase was dried (Na 2 SO 4 ) and it was evaporated. The residue was chromatographed (see compound 10) to give product 11 (12.3 g, 88%) as a colourless oil. The 1 H and 13 C NMR spectra corresponded to those reported (Kaiwar et al., 1995) . 1.27) , 57 (100.0); EI-HRMS calculated for C 12 H 14 O 2 190.0994, found 190.0997. . 1-Butyl lithium (1.6 M in hexanes, 60 ml, 96 mmol) was added dropwise to a stirred suspension of methyltriphenylphosphonium bromide (42.8 g, 120 mmol) in THF Figure 1. Unsaturated nucleoside analogues 1-4, pronucleotides 5 and phosphorylating agent 6 (500 ml) at room temperature. The stirring was continued for 3 h whereupon a solution of compound 11 (14 g, 73.7 mmol) in THF (100 ml) was added. After 30 min, the reaction was quenched with saturated NH 4 Cl (50 ml). The organic layer was washed with water (3×300 ml), it was dried (Na 2 SO 4 ) and evaporated. The residue was chromatographed on a silica gel column using EtOAc:hexanes (1:30) to afford product 12 (11.5 g, 82%) as a colourless oil. 1 H NMR δ 2.43 and 2.48 (2m, 2H), 2.62 (m, 1H), 2.76-2.87 (m, 2H, H 1 +H 2 +H 4 ), 3.51 (d, 2H, J=7.2 Hz, 1-CH 2 ), 4.55 (s, 2H, CH 2 of Bn), 4.78 (t, 2H, J=2.4 Hz, CH 2 =), 7.33 (m, 5H, Ph); 13 C NMR 29.9 (C 1 ), 35.1 (C 2 +C 4 ), 73.3, 74.6 (1-CH 2 , CH 2 of Bn), 106.6 (CH 2 =), 127.8, 127.9, 128.6, 138.8 (Ph) O: C, 82.94; H, 8.57. Found: C, 82.91; H, 8.52 .

m-Chloroperoxybenzoic acid (max. 77%, 8.11 g, max. 36 mmol) was added in portions to a stirred mixture of methylenecyclobutane 12 (4.14 g, 22 mmol) and NaHCO 3 (3.70 g, 44 mmol) in CH 2 Cl 2 (150 ml) at 0°C. The stirring was continued for 4 h and the reaction mixture was diluted with ether (250 ml). The organic phase was washed with saturated Na 2 S 2 O 3 (3×200 ml) and water (2×200 ml), it was dried (Na 2 SO 4 ) and evaporated. The residue was chromatographed as described for compound 10 to give oxaspirohexane 13 (3.82 g, 85%) as a colourless oil. 1 (14) . A mixture of NaH (60% oil dispersion, 637 mg, 15.93 mmol) and adenine (2.48 g, 18.4 mmol) in DMF (100 ml) was stirred at room temperature for 5 h. A solution of oxaspirohexane 8 (2.5 g, 12.25 mol) in DMF (5 ml) was then added dropwise. The stirring was continued for 16 h and then for 4 h at 70°C. The solvent was evaporated in vacuo and the residue was chromatographed using CH 2 Cl 2 :MeOH C NMR 26.1, 26.2, 35.8, 37.2, 52.4, 54.5, 71.6, 72.4, 73.5, 73.7, 73.8, 119.5, 119.8, 127.8, 127.9, 128.2, 128.3, 128.7, 128.8, 138.3, 138.6, 142.0, 150.4, 150.7, 152.6, 152.9, 155.8; 5.5) , 248 (M -Bn, 18.7), 191 (100.0); EI-HRMS calculated for C 18 H 21 N 5 O 2 339.1695, found 339.1697. Analysis calculated for C 18 H 21 N 5 O 2 : C, 63.70; H, 6.24; N, 20.63. Found: C, 63.84; H, 6.16; N, 20.46 . (15) . Methylsulfonyl chloride (1 ml, 12.99 mmol) was added dropwise with stirring to a solution of compound 14 (1.47 g, 4.33 mol) in pyridine (40 ml) at 0°C. The stirring was continued for 16 h at room temperature. Pyridine was evaporated in vacuo and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (50:1) to give product 15 (1.56 g, 86%) as a pale yellow solid. Repeated chromatography separated both isomers. Faster moving isomer: Mp 157-159°C; UV max (EtOH) 260 nm (ε 13900), 208 (ε 27000). 1 .4 (C 6′ , CH 2 of Bn), 84.7 (C 2′ ), 119.2 (C 5 ), 127.9, 128.0, 128.7 and 138.4 (Ph), 141.9 (C 8 ), 151.0 (C 4 ), 153.4 (C 2 ), 155.9 (C 6 ). ESI-MS (MeOH/NaCl) 857 (2M+Na, 63.6), 440 (M+Na, 100.0), 418 (M+H, 6.5). A mixture of both isomers was used in the following experiment. nine (16) . Potassium tert-butoxide (245 mg, 2.19 mmol) was added with stirring to a solution of (E,Z)-mesylate 15 (610 mg, 1.46 mmol) in THF (30 ml) at 0°C. The stirring was continued for 8 h at room temperature. The reaction was quenched by a careful addition of 1M HCl (1 ml) at 0°C. The solvents were evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (50:1) to give product 16 (340 mg, 72%) as a white solid. C NMR 31.4, 32.4, 33 .6 (C 3′ , C 4′ , C 5′ ), 73.4, 73.6 (CH 2 of Bn, C 6′ ), 113.1 (C 1′ ), 119.2 (C 5 ), 127.9, 128.0, 128.7, 138.45, 138.52 (Ph, C 8 ), 133.2 (C 2′ ), 149.2 (C 4 ), 153.5 (C 2 ), 155.7 (C 6 ); EI-MS 321 (M, 3.0), 182 (100.0). EI-HRMS calculated for C 18 H 19 N 5 O: 321.1589, found: 321.1590.
9-{[3-(Benzyloxymethyl)cyclobutylidene]methyl}ade-
9-{[3-(Hydroxymethyl)cyclobutylidene]methyl}ade-
nine (4a). Boron trichloride (1 M in CH 2 Cl 2 , 24.3 ml, 24.3 mmol) was added dropwise to a stirred solution of compound 16 (780 mg, 2.43 mmol) in CH 2 Cl 2 (80 ml) at -78°C. The stirring was continued at -78°C for 6 h whereupon methanol (5 ml) was added followed by NaHCO 3 (5 g) and the mixture was stirred at room temperature for 5 h. The solid was filtered off, it was washed with CH 2 Cl 2 :MeOH (3:1, 100 ml), solvents were evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (15:1→10:1) to give product 4a (400 mg, 75%) as a white solid. Mp 201-202°C; UV max (EtOH) 261 nm (ε 14600), 225 (ε 28800); 1 H NMR (DMSO-d 6 ) δ 2.48-2.59 (m, 2H), 2.65-2.72 (m, 1H), 2.80-2.87 (m, 1H) and 2.90-2.97 (m, 1H, H 3′ , H 4′ , H 5′ ), 3.44 (t, 2H, J=5.8 Hz, H 6′ ), 4.65 (t, 1H, J=5.4 Hz, OH), 6.77 (t, 1H, H 1′ ), 7.29 (s, 2H, NH 2 ), 8.13 (s, 2H, H 2 +H 8 ); 13 C NMR 32.1, 33.2 (C 3′ , C 5′ ), 33.5 (C 4′ ), 65.1 (C 6′ ), 113.1 (C 1′ ), 118.7 (C 5 ), 133.0 (C 2′ ), 138.9 (C 8 ), 149.0 (C 4 ), 153.5 (C 2 ), 156.7 (C 6 ); EI-MS 231 (M, 22.4), 214 (M-OH, 13.4), 69 (100.0); EI-HRMS calculated for C 11 H 13 N 5 O: 231.1120, found: 231.1115. Analysis calculated for C 11 H 13 N 5 O: C, 57.13; H, 5.67; N, 30.28. Found: C, 56.93; H, 5.79; N, 30.40 . (17). 2-Amino-6chloropurine (5.98 g, 35.4 mmol) and NaH (60% oil dispersion, 1.4 g, 35 mmol) in DMF (100 ml) were stirred at room temperature for 5 h. A solution of oxaspirohexane 13 (2.25 g, 11 mmol) in DMF (3 ml) was then added and the stirring was continued for 16 h. The solvent was evaporated and residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (30:1) to give compound 17 (2.8 g, 68%) as a white solid. Mp 54-57°C; UV max (EtOH) 310 nm (ε 8100), 247 (ε 6000), 224 (ε 27700); 1 H NMR (CDCl 3 ) δ 1.82-1.90 (m, 1H), 2.09 (m, 2H), 2.26-2.29 (m, 1.5H) and 2.58-2.70 (m, 0.5H, H 3′ , H 4′ , H 5′ ), 3.44 (poorly resolved d) and 3.48 (d, 2H, J=4.8 Hz, H 6′ ), 4.15 and 4.17 (2s, 2H, H 1′ ), 4.48 and 4.51 (2s, 2H, CH 2 of Bn), 4.68 (s, 0.5H) and 5.08 (s, 0.5H, OH), 5.53 and 5.56 (2s, 2H, NH 2 ), 7.27-7.34 (m, 5H, Ph), 7.46 (s, 0.5H) and 7.90 (s, 0.5H, H 8 ); 13 C NMR 26. 0, 26.3, 35.9, 37.3, 51.6, 53.5, 71.4, 72.5, 73.3, 73.4, 73.5, 73.7, 124.7, 124.9, 127.9, 128.1, 128.7, 128.8, 138.2, 138.5, 143.9, 144.1, 151.2, 151.4, 154.3, 154.5, 159.1, 159.3 ; ESI-MS (NaCl/MeOH) 771, 769 (2M+Na, 59.3, 85.9), 398, 396 (M+Na, 40.7, 59.3, 100.0), 376, 374 (M+H, 29.9, 69.8) . Analysis calculated for C 18 H 20 ClN 5 O 2 : C, 57.83; H, 5.39; N 18.73; Cl, 9.48. Found: C, 57.66; H, 5.50; N, 18.62; Cl, 9.61 . C NMR 27.3, 27.5, 34.1, 35.3, 40.9, 49.2, 50.3, 71.9, 72.7, 73.4, 73.5, 84.3, 88.3, 124.9, 125.0, 127.8, 127.9, 128.0, 128.1, 128.6, 128.7, 138.3, 138.4, 143.4, 143.6, 151.6, 151.7, 154.6, 154.8, 159.4, 159. (19) . Mesylate 18 (720 mg, 1.59 mmol) was added to NaH (76 mg, 60% oil dispersion, 1.90 mmol) in THF:DMF (4:1, 50 ml) with stirring at 0°C. The stirring was then continued at room temperature for 8 h. The solvents were evaporated and the residue was chromatographed on a silica gel column in hexanes:EtOAc (1:1) to give product 19 (317 mg, 56%) as a white solid. Mp 176-178°C; UV max (EtOH) 310 nm (ε 8000), 233 (ε 31000), 206 (ε 30500); 1 H NMR (CDCl 3 ) δ 2.66-2.81 (m, 3H) and 2.95-3.02 (m, 2H, H 3′ , H 4′ , H 5′ ), 3.54 (m, 2H, H 6′ ), 4.54 (s, 2H, CH 2 of Bn), 5.20 (s, 2H, NH 2 ), 6.66 (t, 1H, J=2.4 Hz, H 1′ ), 7.27-7.36 (m, 5H, Ph), 7.81 (s, 1H, H 8 ); 13 C NMR 31.3 (C 4′ ), 32.4, 33.5 (C 3′ , C 5′ ), 73.4 (CH 2 of Bn, C 6′ ), 112.6 (C 1′ ), 127.9, 128.0, 128.7, 138.4 (Ph, C 5 ), 134.1 (C 2′ ), 140.3 (C 8 ), 151.8 (C 4 ), 152.7 (C 2 ), 159.4 (C 6 ); ESI-MS (NaCl/MeOH) 380, 378 (M+Na, 29.8, 100.0), 358, 356 (M+H, 5.4, 14. 3). (20) . Boron trichloride (1 M in CH 2 Cl 2 , 12.4 ml, 12.4 mmol) was added dropwise to a solution of 19 (440 mg, 1.24 mmol) in CH 2 Cl 2 (50 ml) at -78°C. The reaction mixture was stirred at -78 to -40°C for 5 h, whereupon MeOH (5 ml) was added followed by NaHCO 3 (3 g). The mixture was stirred for 16 h at room temperature, the solid was filtered off and it was washed with CH 2 Cl 2 :MeOH (4:1, 50 ml). Solvents were evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (19:1) , 4.55; N 26.36; Cl, 13.34. Found: C, 49.51; H, 4.35; N, 26.21; Cl, 13 .09.
2-Amino
-6-chloro-9-{[3-(benzyloxymethyl)cyclobutyli- dene]methyl}purine
-6-chloro-9-{[3-(hydroxymethyl)cyclobutyli- dene]methyl}purine
9-{[3-(Hydroxymethyl)cyclobutylidene]methyl}guanine (4b).
A solution of compound 20 (200 mg, 0.75 mmol) in HCO 2 H (80%, 50 ml) was heated at 100°C for 6 h with stirring. Volatile components were evaporated in vacuo, the residue was dissolved in NH 3 /MeOH (4%, 25 ml) and the mixture was stirred at room temperature for 30 min. After evaporation, the residue was washed with cold MeOH to give product 4b as a white solid after recrystallisation from aqueous methanol (145 mg, 59%). Mp 310-312°C; UV max (EtOH) 268 nm (ε 10500), 228 (ε 24100); 1 H NMR (DMSO-d 6 ) δ 2.45-2.55 (m, 2H), 2.55-2.65 (m, 1H), 2.74-2.84 (m, 1H) and 2.84-2.92 (m, 1 H, H 3′ , H 4′ , H 5′ ), 3.41 (s, 2H, H 6′ ), 4.66 (bs, 1H, OH), 6.51 and 6.55 (2 overlapped s, 3H, H 1′ , NH 2 ), 7.69 (s, 1H, H 8 ); 13 C NMR 32.0, 33.0 (C 3′ , C 5′ ), 33.5 (C 4′ ), 65.1 (C 6′ ), 113.4 (C 1′ ), 116.5 (C 5 ), 132.4 (C 2′ ), 135.4 (C 8 ), 150.6 (C 4 ), 154.5 (C 2 ), 157.4 (C 6 ); ESI-MS (NaCl/MeOH) 270 (M+Na, 26.3), 248 (M+H, 100.0). Analysis calculated for C 11 H 13 N 5 O 2 : C, 53.43; H, 5.30; N, 28.32. Found: C, 53.26; H, 5.44; N, 28.16 . (21) . A mixture of N 4 -acetylcytosine (1.40 g, 9.12 mmol) and NaH (60% oil dispersion, 550 mg, 13.75 mmol) in DMF (90 ml) was stirred at room temperature for 4 h. A solution of oxirane 13 (930 g, 4.56 mol) in DMF (10 ml) was added and the stirring was continued for 10 h and at 80°C for 8 h. After addition of EtOH (10 ml), the mixture was stirred at 80°C for another 10 h and the volatile components were evaporated in vacuo. The residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (19:1→9:1) to give compound 21 (800 mg, 56%) as a white solid. Mp 208-210°C; UV max (EtOH) 276 nm (ε 8100), 208 (ε 27100); 1 H NMR (DMSO-d 6 ) δ 1. C NMR 25.4, 26.5, 36.7, 38.2, 55.0, 56.9, 71.5, 72.5, 72.6, 73.0, 74.7, 74.9, 93.3, 93.4, 127.9, 128.0, 128.1, 128.9, 139.3, 139.4, 147.8, 147.9, 157.5, 157.8, 166.5, 166.6 , 6.71; N, 13.32. Found: C, 64.53; H, 6.64; N, 13.06 . (22) . Benzoic anhydride (516 mg, 2.28 mmol) was added to a refluxing solution of compound 21 (720 mg, 2.28 mmol) in ethanol (50 ml) every 1 h (total of 6 equivalents). Ethanol was evaporated, the residue was dissolved in CH 2 Cl 2 (150 ml) and it was washed with saturated aqeous NaHCO 3 (3×150 ml) and water (3×150 ml). The organic phase was dried over Na 2 SO 4 , it was evaporated and the residue was chromatographed on a silica gel column in CH 2 Cl 2 :MeOH NMR 26.0, 26.1, 36.4, 37.6, 56.7, 59.4, 73.3, 73.4, 73.7, 73.8, 96.7, 96.9, 127.8, 127.9, 128.3, 128.5, 128.7, 128.9, 129.2, 133.1, 133.2, 133.3, 133.4, 138.3, 138.4, 151.0, 157.4, 158.1, 162.6, 162.7, 167 .0; ESI-MS (MeOH/NaCl/KCl) 458 (M+K, 100.0), 442 (M+Na, 51.8), 420 (M+H, 16.1).
( E , Z ) -1 -{ N 4 -B e n z o y l -[ 3 -( b e n z y l o x y m e t h y l ) -1methylsulfonyloxycyclobutyl]methyl}cytosine (23).
Methylsulfonyl chloride (1.39 ml, 17.9 mmol) was added dropwise to a solution of compound 22 (750 mg, 1.79 mol) in pyridine (50 ml) at 0°C. The stirring was continued at room temperature for 16 h. The solvent was evaporated, the residue was dissolved in CH 2 Cl 2 (100 ml) and it was washed with water (3×100 ml). Organic layer was dried over Na 2 SO 4 and it was evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (40:1) to give the E,Z-mesylate 23 (730 mg, 82%) as a syrup. 1 C NMR 27.3, 28.2, 34.8, 35.0, 40.9, 41.1, 54.1, 55.6, 72.0, 72.6, 73.3, 73.6, 85.7, 89.6, 97.1, 127.84, 127.89, 127.94, 128.0, 128.1, 128.6, 128.7, 129.3, 133.3, 133.4, 138.3, 138.4, 150.2, 162.6, 162.7 . ESI-MS (MeOH/NaCl) 498 (M+H, 18.0), 520 (M+Na, 100.0). sine (25) . Potassium tert-butoxide (316 mg, 2.82 mmol) was added to a stirred solution of mesylate 23 (700 mg, 1.41 mmol) in THF (50 ml) at 0°C. The stirring was continued at room temperature for 16 h whereupon the reaction was quenched by a cautious addition of 1M HCl (1 ml) at 0°C. The volatile components were evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (40:1) to give N-benzoyl derivative 24 (500 mg, 88%) as a solid which was used as such in the subsequent experiment. UV max (EtOH) 323 nm (ε 10000), 264 (ε 16000), 205 (ε 35000). 1 A solution of compound 24 (500 mg, 1.25 mmol) in NH 3 /MeOH (20%, 50 ml) was stirred at room temperature for 6 h. Volatile components were evaporated and the residue was chromatographed on a silica gel column in CH 2 Cl 2 :MeOH (19:1) to give product 25 (300 mg, 81%) as a white solid. Mp 208-210°C; UV max (EtOH) 290 nm (ε 11100), 230 (ε 13000), 205 (ε 25100); 1 H NMR (DMSO-d 6 ) δ 2.48-2.66 (2 m, 3H) and 2.66-2.81 (m, 2H, H 3′ , H 4′ , H 5′ ), 3.45 (d, 2H, J=6.4 Hz, H 6′ ), 4.44 (s, 2H, CH 2 of Bn), 5.72 (d, 1H, J=7.2 Hz, H 5 ), 6.50 (bs, 1H, H 1′ ), 7.10 (s, 1H) and 7.21-7.30 (m, 6H, NH 2 and Ph), 7.36 (d, 1H, J=7.6 Hz, H 6 ); 13 C NMR 31.5 (C 4′ ), 32.67, 32.72 (C 3′ , C 5′ ), 72.9, 73.8 (CH 2 of Bn, C 6′ ), 94.7 (C 5 ), 120.0 (C 1′ ), 127.9, 128.0, 128.7, 128.8, 139.0 (C 6 H 5 , C 2′ ), 143.0 (C 6 ), 155.2 (C 4 ), 166.1 (C 2 ); ESI-MS 617 (MeOH/NaCl) 617 (2M+Na, 28.1), 595 (2M+H, 20.4), 320 (M+Na, 100.0), 298 (M+H, 36.5). Analysis calculated for C 17 H 19 N 3 O 2 : C, 68.67; H, 6.44; N 14.13. Found: C, 68.54; H, 6.38; N, 14.11. sine (4c) . Boron trichloride (1 M in CH 2 Cl 2 , 8.08 ml, 8.08 mmol) was added dropwise to a solution of compound 25 (240 mg, 0.81 mmol) in CH 2 Cl 2 (100 ml) at -78°C. The reaction mixture was stirred at -78 to -40°C for 4 h. Methanol (5 ml) was then added followed by NaHCO 3 (3 g) to quench the reaction, the mixture was stirred at room temperature for 16 h, the solids were filtered off and they were washed with CH 2 Cl 2 : MeOH (3:1, 50 ml) . The solvents were evaporated and the residue was chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (9:1→85:15) to give compound 4c (140 mg, 84%) as a white solid, which was recrystallized from ethanol. Mp 198-200°C; UV max (EtOH) 290 nm (ε 10900), 229 (ε 13 100), 205 (ε 18 000); 1 H NMR (DMSO-d 6 ) δ 2.40-2.53 (2 overlapped m, 3H) and 2.67-2.72 (m, 2H, H 3′ , H 4′ , H 5′ ), 3.40 (poorly resolved d, 2H, H 6′ ), 4.65 (bs, 1H, OH), 5.71 (d, 1H, J=7.2 Hz, H 5 ), 6.46 (poorly resolved t, 1H, H 1′ ), 7.28, 7.23 (2bs, 2H, NH 2 ), 7.47 (d, 1H, J=7.2 Hz, H 6 ); 13 C NMR 32.17, 32.23 (C 3′ , C 5′ ), 33.8 (C 4′ ), 65.1 (C 6′ ), 94.5 (C 5 ), 119.1 (C 1′ ), 129.6 (C 2′ ), 143.6 (C 6 ), 155.1 (C 4 ), 166.2 (C 2 ). Analysis calculated for C 10 H 13 N 3 O 2 : C, 57.96; H, 6.32; N 20.28. Found: C, 57.84; H, 6.22; N, 20.11 .
1-{[3-(Benzyloxymethyl)cyclobutylidene]methyl}cyto-
1-{[3-(Hydroxymethyl)cyclobutylidene]methyl}cyto-
9-{[3-(Hydroxymethyl)cyclobutylidene]methyl}adenine (methylphenylphosphoryl)-(P→N)-alaninate (5a).
A suspension of compound 4a (160 mg, 0.69 mol) in pyridine (15 ml) was sonicated for 10 min. Phenyl chlorophosphoralaninate (6) in THF (0.23 M, 12.4 ml, 2.85 mmol) was then added with stirring followed by N-methylimidazole (0.55 ml, 6.93 mmol). The stirring at room temperature was continued for 16 h. The solvents were evaporated, residue was dissolved in CH 2 Cl 2 , organic phase was washed with water and dried over Na 2 SO 4 . After evaporation, the crude product chromatographed on a silica gel column using CH 2 Cl 2 :MeOH (30:1→20:1) to give the phosphoralaninate 5a (124 mg, 38%) as a white solid. UV max (EtOH) 261 nm (ε 13400), 224 (ε 24800), 209 (ε 29500); 1 H NMR (CDCl 3 ) δ 1.33 and 1.35 (m, 3H, Me of Ala), 2.64-2.83 (m, 3H) and 2.9 (m, 2H, H 3′ , H 4′ , H 5′ ), 3.64, 3.66 and 3.67 (3s, 3H, MeO), 3.95-4.10 and 4.10-4.20 (2m, 3H, H 6′ , CH of Ala), 4.57-4.73 (m, 1H, NH of Ala), 6.48 (s, 2H, NH2), 6.79 (poorly resolved t, 1H, H 1′ ), 7. 5H, Ph), 7.80, 7.81, 7.82 (3s, 1H) and 8.31 (1s, 1H, H 8 , H 2 ); 13 C NMR 31.4, 31.5, 31.7 (split peak), 32.7, 32.8 (C 3′ , C 4′ , C 5′ ), 69.46, 69.54 (C 6′ ), 113.4 (C 1′ ), 131.5 (split peak, C 2′ ); alanine: 21.0, 21.18 (split peak), 21.24 (Me), 50.4, 50.5 (CH), 52.7 (MeO), 174.3 (split peak, C=O); Ph: 120.40 (split peak), 125.1, 129.8, 151.0 (split peak); adenine: 118.9 (C 5 ), 138. , 52.39; H, 5.44; N, 17.46. Found: C, 52.17; H, 5.84; N, 17.21 .
9-{[3-(Hydroxymethyl)cyclobutylidene]methyl}guanine (methylphenylphosphoryl)-(P→N)-alaninate (5b).
The reaction was perfomed with guanine analogue 4b on a 0.5 mmol scale as described above for adenine phosphoralaninate 5a. The crude product was chromatographed using CH 2 Cl 2 :MeOH (40:1) and then EtOAc:MeOH (4:1) to give compound 5b (70 mg, 29%) as a white solid. UV max (EtOH) 267 nm (ε 10500), 225 (ε 24800); 1 H NMR (DMSO-d 6 ) δ 1.19 (apparent t, 3H, Me of Ala), 2.48-2.62 (m), 2.66-2.71 (m), 2.83-2.89 (m) and 2.98 (m, 5H, H 3′ , H 4′ , H 5′ ), 3.56 and 3.57 (2s, 3H, MeO), 3.79-3.86 (m, 1H, CH of Ala), 3.99-4.07 (m, 2H, H 6′ ), 5.94-6.04 (m, 1H, NH of Ala), 6.50, 6.55, 6.56 (3s, 3H, NH 2 , H 1′ ), 7.13-7.18 (m, 3H) and 7. 2H, Phe), 7.67, 7.68, 7.69, 7.70 (4s, 1H, H8) , 10.64 (s, 1H, NH); 31 P NMR 4.57, 4.58, 4.96; ESI-MS (MeOH/NaCl) 999 (2M+Na, 24.0), 511 (M+Na, 100.0 ), 489 (M+H, 5.3). Analysis calculated for C 21 H 25 N 6 O 6 P•CH 3 OH: C, 50.77; H, 5.62; N, 16.15; P, 5.95. Found: C, 50.41; H, 5.22; N, 15.85 ; P, 6.21.
Virology
General methods. Adenosine deaminase from calf intestinal mucosa (EC 3.5.4.4, Type II, 1.5 units/mg) and porcine liver esterase (EC 3.1.1.1, suspension in 3.2 M ammonium sulfate, 5440 units/ml) were obtained from Sigma-Aldrich (St. Louis, Mo.).
Antiviral assays for EBV. The effective concentration (EC 50 ) is defined as a concentration of analogue in µM, which results in 50% inhibition of the virus replication. The cytotoxic concentration (CC 50 ) reflects then a concentration causing 50% inhibition of growth of uninfected host cells.
Preparation of infected cells. Daudi cells at 1×10 6 were incubated with EBV stock virus obtained from P3HR-1 cells at a concentration sufficient to infect 10% of the cells. The P3HR-1 strain for EBV was obtained from American Type Culture Collection, Manassas, VA, USA. After incubation at 37°C for 1 h, the cells were rinsed and pelleted by centrifugation. Appropriate concentrations of drug were added to infected cells in culture tubes and incubated for 3 days at 37°C. The cells were then spotted onto slides or into 96-well plates and fixed with acetone or acetic acid/ethanol. (ELISA) . ELISA was performed on fixed Daudi cells by incubation first with a monoclonal antibody to EBV viral capsid antigen (Chemicon, Temecula, Calif., USA) followed by an incubation with horseradish peroxidase-labeled goat antimouse IgG1 (Southern Biotechnology, Birmingham, Ala., USA). The colourimetric reaction was initiated by addition of o-phenylenediamine dihydrochloride in citrate buffer (pH 5.0) and hydrogen peroxide and the reaction was stopped by the addition of 3 N sulfuric acid and read on a microplate reader (Bio-Tek Instruments, Winooski, Vt., USA). The EC 50 value for each drug was extrapolated from the plot of drug concentration versus average optical density at 492 nm (OD 492 ) for each concentration of drug. Acyclovir (ACV) was used as a positive control.
Enzyme-linked immunosorbent assay
In situ hybridization assay. The Simply Sensitive Horseradish Peroxidase-AEC In Situ Detection System (Enzo Diagnostics, Farmingdale, New York, NY, USA) was used to monitor EBV DNA synthesis in the presence of antiviral compounds and was performed according to the manufacturer's instructions. Cells were counted using a light microscope at a 400× magnification. The EC 50 value for each drug was extrapolated from the plot of drug concentration versus the percentage of positive cells.
Determination of cytotoxicity for Daudi and HFF cells.
Daudi cells were added to tubes at a concentration of 1×10 6 per tube. Drug concentrations ranging from 50 to 0.08 µg/ml was added to each tube and allowed to incubate at 37°C for three days. After incubation, samples were taken from each tube and cytotoxicity was determined by trypan blue uptake. Live cells were counted using a light microscope at a 100× magnification. The 50% cytotoxicity concentration (CC 50 ) was determined by plotting the drug concentration versus the concentration of living cells. Cytotoxicity for human foreskin fibroblast (HFF) cells was also determined using a neutral red uptake assay in stationary, non-dividing cells. Cells were seeded into 96-well plates at a concentration of 2.5×10 4 cells/well. After 24 h, media was aspirated and 100 µg of drug was added to the first row and serially diluted 1:5 to a concentration of 0.03 µg. The plates were incubated for 7 day, media aspirated, cells stained with neutral red and incubated for 1 h. The cells were washed and solubilising solution (50% ethanol, 1% acetic acid) was added. The plates were shaken for 15 min on a rotating shaker and optical densities read at 550 nm. The effect on cell proliferation was determined by seeding cells in 6 well plates at a concentration of 2.5×10 4 cells/well. After 24 h, the media was aspirated and drug was added and serially diluted as above. Cells were incubated for 72 h at 37°C (approximately three growth cycles) trypsinised and counted using a Beckman Coulter Counter. The 50% inhibitory concentration was calculated using a computer program (MacSynergy II).
Deamination of methylenecyclobutane 4a. The reaction was performed as described by Qiu et al. (1998a) . A mixture of compound 4a (0.6 mg, 2.6 µmol) and adenosine deaminase (0.45 unit) was stirred in 0.02 M Na 2 HPO 4 (pH 7.5, 0.4 ml) at room temperature. Aliquots were periodically withdrawn and examined by TLC in CH 2 Cl 2 :MeOH (9:1). The spots of 4a and deamination product were eluted with ethanol and absorbance at 261 (4a) or 254 nm (deamination product) was determined using ε max 13900 and 10500, respectively. The results are shown in Figure 5 . Hydrolysis of 5a and 5b with porcine liver esterase (PLE) The standard procedure (Winter et al., 1996) was followed. Compound 5a or 5b (0.8 mg, 1.6-1.7 µmol) was stirred with PLE (200 units) in 0.02 M Na 2 HPO 4 (pH 7.4, 1 ml) at 37°C for 14-18 h. TLC (CH 2 Cl 2 :MeOH=4:1) indicated a quantitative hydrolysis of 5a and 5b.
Results
Chemical synthesis
The synthetic approach was based on a successful elaboration of oxaspiropentane 13 (Figure 2) as a key intermediate, which was then employed for alkylation of nucleic acid base or suitable precursor. A similar method was recently used for synthesis of methylenecyclobutane 3 and the corresponding E-isomer (Guan et al., 2000b) . The known (Pigou & Schiesser, 1988) 3-oxocyclobutane carboxylic acid (7) was first transformed to acetal ester 8 in 97% yield by a modification of the described procedure (Stevens & De Kimpe, 1996) using 0.5% HCl in methanol. Reduction with LiAlH 4 afforded acetal carbinol 9 (85%), which was then alkylated with benzyl bromide and NaH in DMF, to give the fully protected intermediate 10 (89%). Deacetalation using p-toluenesulfonic acid in aqueous acetone gave cyclobutanone 11 (88%), which was identical with a product obtained by a different route (Kaiwar et al., 1995) . The Wittig methylenation using triphenylphosphonium methylid in THF afforded methylenecyclobutane 12 in 82% yield. Epoxidation with m-chloroperoxybenzoic acid and NaHCO 3 in CH 2 Cl 2 (Guan et al., 2000b) furnished the required oxaspirohexane 13 (85%).
Alkylation of sodium salt of adenine with 13 in DMF ( Figure 2) led to E,Z-hydroxycyclobutane 14 (56%). Reaction with methylsulfonyl chloride in pyridine which afforded methylsulfonate 15 (86%) was followed by βelimination using potassium tert-butoxide in THF to give the protected methylenecyclobutane 16 in 72% yield. Debenzylation with BCl 3 in CH 2 Cl 2 (Guan et al., 2000b) furnished adenine analogue 4a (75%).
In a similar vein, alkylation of 2-amino-6-chloropurine with oxaspirohexane 13 gave E,Z-hydroxycyclobutane 17 (68%, Figure 3 ). Due to a likely interaction of 6-chlorop- urine moiety with pyridine (Adamiak et al., 1985) , subsequent reaction with methylsulfonyl chloride was performed in CH 2 Cl 2 using N-ethyl-N,N-diisopropylamine as a base to afford methylsulfonate 18 in 60% yield. β-elimination using NaH in THF/DMF furnished methylenecyclobu-tane 19 (56%). Debenzylation with BCl 3 in CH 2 Cl 2 gave 2-amino-6-chloropurine derivative 20 (81%). Routine hydrolysis with 80% formic acid (Qiu et al., 1998a) followed by treatment with NH 3 in methanol provided guanine analogue 4b (59%). Alkylation of N 4 -acetylcytosine with oxaspirohexane 13 performed at an elevated temperature (80°C) led to a removal of N-acetyl group to give intermediate 21 in 56% yield (Figure 4) . The latter product was selectively N-benzoylated using benzoic anhydride in refluxing ethanol (Qiu et al., 1998b) to afford N-benzoyl derivative 22 (78%). Methylsulfonylation (23, 82%) and β-elimination (24, 88%) were performed as described for the respective adenine derivatives 15 and 16 (Figure 2) . Routine debenzoylation of 24 with NH 3 in methanol furnished intermediate 25 (81%). Finally, debenzylation with BCl 3 in CH 2 Cl 2 provided cytosine analogue 4c in 84% yield.
Antiviral activity
Analogues 4a, 4b, 4c and phosphoralaninate 5b were inactive (EC 50 /CC 50 (µM) >100/>100) against all tested viruses (HIV-1, HBV, HSV-1, HSV-2, HCMV, EBV and VZV). Pronucleotide 5a was effective against EBV in Daudi cells. The EC 50 /CC 50 (µM) values were as follows: <0.17/>104 (acyclovir 8.4/>444) in viral capsid antigen (VCA) ELISA and 2.0/>104 (acyclovir 0.44/>444) in DNA hybridization assay. Phosphoralaninate 5a was noncytotoxic toward stationary (CC 50 >208, acyclovir >444 µM) and proliferating HFF cells (CC 50 110, acyclovir >444 µM) as well as dividing Daudi cells (CC 50 >104, acyclovir >222 µM). Adenine and guanine pronucleotides 5a and 5b are substrates for porcine liver esterase. Adenine analogue 4a is a moderate substrate (t 1/2 =53 h) for adenosine deaminase ( Figure 5 ).
Discussion
Antiviral activity of phenylphosphoralaninate 5a is an example of an inactive analogue (4a) that is activated by a lipophilic phosphoramidate group capable of producing phosphorylated intermediates inside the cells. Interestingly, obviating the first phosphorylation step is not sufficient to overcome restrictions imposed by further activation steps in viruses other than EBV. It should be also noted that compound 4a is racemic and due to a chiral phosphorus atom, pronucleotide 5a is a mixture of four diastereoisomers. Its parent analogue 4a has an N9-CH 2 (O) distance 5.5 Å, which puts it beyond the usual range (approximately 4 Å) found in unsaturated analogues with antiviral activity (Zemlicka, 2002a) . Nevertheless, a potent antiviral activity including anti-EBV effect was seen (Guan et al., 2000a) in a distal spiropentane analogue of guanine 26a (Figure 6 ), where this distance is 5 Å. It is then clear that distances N9-CH 2 (O) >4 Å are compatible with antiviral activity, at least of some analogues. The results with compound 5a indicate for the first time that pronucleotides derived from such analogues can also exhibit antiviral activity. A lack of cytotoxicity of analogue 5a, both in stationary and proliferating cells, is of significant interest. This is in contrast to phenylphosphoralaninates derived from allenic or methylenecyclopropane analogues, where the antiviral effect is frequently accompanied by an increased cytotoxicity (Zemlicka, 2002b; Qiu et al., 1999; Uchida et al., 1999) .
A fact that both active (5a) and inactive (5b) pronucleotide are substrates for porcine liver esterase contradicts an earlier proposal that this parameter is a predictor of antviral activity (McGuigan et al., 1998) . It is in line with a later finding (McGuigan et al., 2000) indicating a limited value of this parameter. Most likely, the intracellular processing of phenyl phosphoralaninate 5a follows the pathway established for other similar pronucleotides (Winter et al., 1996; Balzarini et al., 1996) including a step catalyzed by phosphoramidase (Saboulard et al., 1999) .
Deamination of adenine methylenecyclobutane 4a is also of interest. In contrast with their lack of antiviral activity, the E(trans) isomers are generally better substrates than Z(cis) isomers (Zemlicka, 2002a , Qiu et al., 1998a . The , the E-isomer of 3 (4.63 Å) and distal spiropentane derivative 26b (5 Å) are not deaminated ( Jones et al., 1995; Guan et al., 2000b) . Analogue 4a is racemic and the course of deamination ( Figure 5) indicates that both enantiomers are deaminated. It is noteworthy that enantiomers of adenallene 2a, another analogue with an axial chirality, are also substrates for adenosine deaminase (Phadtare & Zemlicka, 1989) . It seems that the presence of a double bond proximal to nucleic acid base in axially chiral analogues 2a and 4a is more conducive to enzyme-catalyzed deamination, whereas the distance factor plays a somewhat lesser role.
